KILITCH.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 12:59):

Stats
Šios dienos apimtis	13 522.00
Vidutinė apimtis	11 316.00
Rinkos kapitalizacija	5.78B
EPS	INR0 ( 2024-02-08 )
Kita pelno data	( INR0 ) 2024-05-27
Last Dividend	INR0.500 ( 2019-09-20 )
Next Dividend	INR0 ( N/A )
P/E	38.96
ATR14	INR1.579 (0.44%)

Tūris Koreliacija

Ilgas: 0.30 (neutral)

Trumpas: 0.41 (neutral)

Signal:(51.683) Neutral

Kilitch Drugs (India) Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Kilitch Drugs (India) Koreliacija - Valiuta/Žaliavos

-0.14
( neutral )

-0.55
( weak negative )

0.01
( neutral )

-0.61
( weak negative )

0.14
( neutral )

0.73
( moderate )

Kilitch Drugs (India) Finansinės ataskaitos

Annual	2022
Pajamos:	INR1.40B
Bruto pelnas:	INR648.40M (46.45 %)
EPS:	INR6.71

FY	2022
Pajamos:	INR1.40B
Bruto pelnas:	INR648.40M (46.45 %)
EPS:	INR6.71

FY	2022
Pajamos:	INR1.14B
Bruto pelnas:	INR488.01M (42.72 %)
EPS:	INR4.73

FY	2021
Pajamos:	INR685.23M
Bruto pelnas:	INR312.16M (45.56 %)
EPS:	INR2.37

Financial Reports:

No articles found.

Kilitch Drugs (India) Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Kilitch Drugs (India) Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.64 - low (54.24%) | Divividend Growth Potential Score: 4.47 - Potential for dividend initiation, but uncertain (10.66%)

Information

First Dividend	INR1.000	2010-10-14
Last Dividend	INR0.500	2019-09-20
Next Dividend	INR0	N/A
Payout Date	2019-10-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	INR33.00	--
Avg. Dividend % Per Year	0.00%	--
Score	1.62	--
Div. Sustainability Score	4.64
Div.Growth Potential Score	4.47
Div. Directional Score	4.56	--

Next Divdend (Est)
(2025-09-01)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

1.62

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.500	0.59%
2019	INR0.500	0.31%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TINPLATE.NS	Dividend Junior	2023-08-11	Annually	19	0.72%
PDMJEPAPER.NS	Dividend Junior	2023-08-03	Annually	9	0.65%
J&KBANK.NS	Dividend Junior	2023-08-17	Sporadic	22	0.47%
DATAMATICS.NS	Dividend Junior	2023-09-22	Annually	21	0.49%
SHYAMMETL.NS	Dividend Junior	2023-06-05	Semi-Annually	4	0.70%
MAXHEALTH.NS	Dividend Junior	2023-09-08	Insufficient data to determine frequency	2	0.07%
GSPL.NS	Dividend Junior	2023-09-01	Annually	19	0.81%
BANKINDIA.NS	Dividend Junior	2023-06-20	Sporadic	23	1.34%
PRAJIND.NS	Dividend Junior	2023-07-19	Annually	22	0.83%
KABRAEXTRU.NS	Dividend Junior	2023-07-13	Annually	23	0.83%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0940	1.500	8.12	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.124	1.500	9.73	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	4.20	1.000	9.56	9.56	[3 - 30]
operatingCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.15	2.00	7.93	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.486	1.000	5.24	5.24	[0.2 - 0.8]
operatingProfitMarginTTM	0.158	1.000	8.85	8.85	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.64

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	39.65	1.000	6.10	0	[1 - 100]
returnOnEquityTTM	0.124	2.50	9.83	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.947	1.500	7.02	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0430	1.000	-1.424	0	[0.1 - 0.5]
Total Score				4.47

Kilitch Drugs (India)

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.